121 related articles for article (PubMed ID: 16580307)
1. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.
Rice LW; Stone RL; Xu M; Galgano M; Stoler MH; Everett EN; Jazaeri AA
Am J Obstet Gynecol; 2006 Apr; 194(4):1119-26; discussion 1126-8. PubMed ID: 16580307
[TBL] [Abstract][Full Text] [Related]
2. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
[TBL] [Abstract][Full Text] [Related]
3. Tumors of the uterine isthmus: clinicopathologic features and immunohistochemical characterization of p53 expression and hormone receptors.
Jacques SM; Qureshi F; Ramirez NC; Malviya VK; Lawrence WD
Int J Gynecol Pathol; 1997 Jan; 16(1):38-44. PubMed ID: 8986531
[TBL] [Abstract][Full Text] [Related]
4. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
5. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
6. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
8. Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K; Sørensen BS; Poulsen SS; Forman A; Nexø E; Mogensen O
Gynecol Oncol; 2007 Jan; 104(1):158-67. PubMed ID: 16962163
[TBL] [Abstract][Full Text] [Related]
9. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.
Yang YC; Wu CC; Chen CP; Chang CL; Wang KL
Gynecol Oncol; 2005 Nov; 99(2):287-93. PubMed ID: 16051341
[TBL] [Abstract][Full Text] [Related]
10. FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium.
Soufla G; Sifakis S; Spandidos DA
Cancer Lett; 2008 Feb; 259(2):146-55. PubMed ID: 18006148
[TBL] [Abstract][Full Text] [Related]
11. Role of bcl-2 in endometrioid corpus cancer: an experimental study.
Mariani A; Sebo TJ; Cliby WA; Keeney GL; Riehle DL; Lesnick TG; Podratz KC
Anticancer Res; 2006; 26(2A):823-7. PubMed ID: 16619475
[TBL] [Abstract][Full Text] [Related]
12. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
[TBL] [Abstract][Full Text] [Related]
13. Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1.
Briese J; Schulte HM; Bamberger CM; Löning T; Bamberger AM
Int J Gynecol Pathol; 2006 Apr; 25(2):161-9. PubMed ID: 16633066
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of tyrosine threonine kinase inhibits tumor growth via G2/M arrest in human endometrioid endometrial adenocarcinoma.
Zhang J; Jiang Y; Zhao Y; Wang W; Xie Y; Wang H; Yang Y
Tumour Biol; 2017 Jul; 39(7):1010428317712444. PubMed ID: 28718377
[TBL] [Abstract][Full Text] [Related]
15. Cytologic scoring of endometrioid adenocarcinoma of the endometrium.
Nishimura Y; Watanabe J; Jobo T; Hattori M; Arai T; Kuramoto H
Cancer; 2005 Feb; 105(1):8-12. PubMed ID: 15597380
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the homeodomain gene EMX2: sequence conservation, expression analysis, and a search for mutations in endometrial cancers.
Noonan FC; Mutch DG; Ann Mallon M; Goodfellow PJ
Genomics; 2001 Aug; 76(1-3):37-44. PubMed ID: 11549315
[TBL] [Abstract][Full Text] [Related]
17. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
[TBL] [Abstract][Full Text] [Related]
19. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas.
Bland AE; Stone R; Heuser C; Shu J; Jazaeri A; Shutter J; Atkins K; Rice L
Int J Gynecol Cancer; 2009 Feb; 19(2):261-5. PubMed ID: 19396006
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
Ramondetta LM; Johnson AJ; Sun CC; Atkinson N; Smith JA; Jung MS; Broaddus R; Iyer RB; Burke T
Cancer; 2009 May; 115(9):1867-74. PubMed ID: 19241422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
